The clinical application of linagliptin in Asians

摘要: Asia has a growing diabetic population. Linagliptin, member of dipeptidyl peptidase-4 inhibitor class, is unique in its nonlinear pharmacokinetics with the characteristics rapid attainment steady state, little accumulation, predominantly nonrenal route elimination, prolonged terminal half-life, and sustained inhibition enzyme. No clinically relevant difference was observed between Asians non-Asians. The management type 2 diabetes increasingly challenging progression disease, especially requirements minimal hypoglycemia, weight gain, fluid retention, other adverse effects. Linagliptin efficacious well-tolerated Asian patients or without renal hepatic dysfunctions, comparable to that Caucasians. This review will focus on usage linagliptin clinical studies Asians.